Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T01840
(Former ID: TTDNC00449)
|
|||||
| Target Name |
Protease unspecific (PRO)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Prolastin | Drug Info | Approved | Alpha-1 antitrypsin deficiency | [1] | |
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | ONO-3307 | Drug Info | Phase 2 | Coagulation defect | [2] | |
| 2 | SRD-441 | Drug Info | Phase 2 | Atopic dermatitis | [3] | |
| 3 | AZD-2551 | Drug Info | Phase 1 | Chronic obstructive pulmonary disease | [4] | |
| Discontinued Drug(s) | [+] 6 Discontinued Drugs | + | ||||
| 1 | Aprosulate sodium | Drug Info | Discontinued in Phase 1 | Coagulation defect | [5] | |
| 2 | AZD-3342 | Drug Info | Discontinued in Phase 1 | Chronic obstructive pulmonary disease | [6] | |
| 3 | ALP-242 | Drug Info | Terminated | Cystic fibrosis | [7] | |
| 4 | CEP-431 | Drug Info | Terminated | Alzheimer disease | [8] | |
| 5 | EP-2060 | Drug Info | Terminated | Solid tumour/cancer | [9] | |
| 6 | WY-48989 | Drug Info | Terminated | Rheumatoid arthritis | [10] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Inhibitor | [+] 4 Inhibitor drugs | + | ||||
| 1 | Prolastin | Drug Info | [1] | |||
| 2 | SRD-441 | Drug Info | [11] | |||
| 3 | AZD-2551 | Drug Info | [12] | |||
| 4 | CEP-431 | Drug Info | [16] | |||
| Modulator | [+] 5 Modulator drugs | + | ||||
| 1 | ONO-3307 | Drug Info | [2] | |||
| 2 | Aprosulate sodium | Drug Info | [13] | |||
| 3 | AZD-3342 | Drug Info | [14] | |||
| 4 | ALP-242 | Drug Info | [15] | |||
| 5 | WY-48989 | Drug Info | [18] | |||
| Inducer | [+] 1 Inducer drugs | + | ||||
| 1 | EP-2060 | Drug Info | [17] | |||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 2 | Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol. 1989 Dec;51(4):455-63. | |||||
| REF 3 | ClinicalTrials.gov (NCT00882245) Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis. U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT00860353) Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551. U.S. National Institutes of Health. | |||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002026) | |||||
| REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019126) | |||||
| REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005125) | |||||
| REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003560) | |||||
| REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013537) | |||||
| REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003820) | |||||
| REF 11 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029807) | |||||
| REF 12 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029854) | |||||
| REF 13 | Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model. Pol J Pharmacol. 1996 May-Jun;48(3):317-22. | |||||
| REF 14 | New Drugs and Targets for Asthma and COPD. Trevor T. Hansel, Peter J. Barnes. 2010. Page(227). | |||||
| REF 15 | Oxidation resistant muteins of antileukoproteinase as potential therapeutic agents. Agents Actions Suppl. 1993;42:111-21. | |||||
| REF 16 | US patent application no. 7,935,815, Imidazoyl pyridine compounds and salts thereof. | |||||
| REF 17 | Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents. Anticancer Agents Med Chem. 2009 May;9(4):437-56. | |||||
| REF 18 | Inhibition of interleukin-1 (IL-1) induced neutral proteases from rabbit articular chondrocytes by WY-46,135 and WY-48,989. Agents Actions. 1991 Sep;34(1-2):223-5. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.